Loading patent…
AssigneeTune Therapeutics, Inc.
InventorsAkiko SEKI, Lucas James THOMPSON, Tyler S. KLANN, Alexandra CROFT, Nathaniel CHARTRAND, Nicole DENAMUR, Andrew HILL, Jason DEAN, Emi TOKUDA, Blythe SATHER
Estimating the term…
Provided are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems, that bind to or target a target site in a gene or regulatory element thereof in a T cell. In some aspects, the provided epigenetic modifying DNA-targeting systems modulate a T cell function, such as a T cell phenotype or activity. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in modulating T cells including in connection with methods of adoptive T cell therapy.
An epigenetic-modifying DNA-targeting system comprising at least one DNA-targeting module for repressing transcription of one or more genes in a T cell, wherein each of the at least one DNA-targeting module comprises a fusion protein comprising:
An epigenetic-modifying DNA-targeting system comprising at least one DNA-targeting module for increasing transcription of one or more genes in a T cell, wherein each of the at least one DNA-targeting module comprises a fusion protein comprising:
The epigenetic-modifying DNA-targeting system of 29 or 31, wherein the first and second gene are IL2 and VAV1.
The epigenetic-modifying DNA-targeting system of 29 or 31, wherein the first and second gene are IL2 and LCP2.
The epigenetic-modifying DNA-targeting system of 29 or 31, wherein the first and second gene are IL2 and TBX21.
The epigenetic-modifying DNA-targeting system of 29 or 31, wherein the first and second gene are IL2 and EOMES.
The epigenetic-modifying DNA-targeting system of 57, wherein the dCas9 protein is a Staphylococcus aureus dCas9 (dSaCas9) protein.
A guide RNA (gRNA) that targets a target site for a gene selected from the group consisting of CBLB, CCNC, CD5, CISH, DGKZ, ELOB, FAS, Fli1, GATA3, KDM1A, MED12, MYB, PRDM1, TGFBR2, and RASA2.
A guide RNA (gRNA) that targets a target site for a gene selected from the group consisting of BATF, CD28, EOMES, IL-2, IL2RB, IRF4, LAT, LCP2, TBX21, and VAV1.
Dependencies are inferred from the claim text.